Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03626545
Title Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy (CANOPY-2)
Acronym CANOPY-2
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | NLD | ITA | FRA | ESP | DEU | CAN | BEL | AUS

Facility Status City State Zip Country Details
Emory Winship Cancer Institute Atlanta Georgia 30322 United States Details
Saint Luke's Hospital/Marion Bloch Neuroscience Institute Dept of Regulatory Kansas City Missouri 64111 United States Details
Montefiore Medical Center Albert Einstein College of Med Bronx New York 10461 United States Details
University of Cincinnati Cancer Institute Cincinnati Ohio 45267 United States Details
MD Anderson Houston Texas 77030 United States Details
Huntsman Cancer Institute Univ of Utah . Salt Lake City Utah 84112 0550 United States Details
Novartis Investigative Site Berazategui Buenos Aires B1884BBF Argentina Details
Novartis Investigative Site Caba Buenos Aires C1426ANZ Argentina Details
Novartis Investigative Site Mar del Plata Buenos Aires B7600FZN Argentina Details
Novartis Investigative Site La Rioja 5300 Argentina Details
Novartis Investigative Site Santiago del Estero 4200 Argentina Details
Novartis Investigative Site Greenslopes Queensland 4120 Australia Details
Novartis Investigative Site Shepparton Victoria 3630 Australia Details
Novartis Investigative Site Sint Niklaas Oost Vlaanderen 9100 Belgium Details
Novartis Investigative Site Bruxelles 1200 Belgium Details
Novartis Investigative Site Charleroi 6000 Belgium Details
Novartis Investigative Site Gent 9000 Belgium Details
Novartis Investigative Site Roeselare 8800 Belgium Details
Novartis Investigative Site Salvador BA 40170-110 Brazil Details
Novartis Investigative Site Porto Alegre RS 90880-480 Brazil Details
Novartis Investigative Site Itajai SC 88301-229 Brazil Details
Novartis Investigative Site Vancouver British Columbia V5Z 4E6 Canada Details
Novartis Investigative Site Montreal Quebec H4A 3J1 Canada Details
Novartis Investigative Site Santiago 7500006 Chile Details
Novartis Investigative Site Chengdu Sichuan 610041 China Details
Novartis Investigative Site Shanghai 200433 China Details
Novartis Investigative Site Brno - Bohunice 625 00 Czechia Details
Novartis Investigative Site Ostrava Vitkovice 703 84 Czechia Details
Novartis Investigative Site Herlev DK 2730 Denmark Details
Novartis Investigative Site Odense C DK 5000 Denmark Details
Novartis Investigative Site Le Mans Cedex 09 72037 France Details
Novartis Investigative Site Besancon Cedex 25030 France Details
Novartis Investigative Site Bordeaux Cedex 33000 France Details
Novartis Investigative Site Bron 69677 France Details
Novartis Investigative Site Strasbourg Cedex 67091 France Details
Novartis Investigative Site Berlin 13125 Germany Details
Novartis Investigative Site Dresden 01307 Germany Details
Novartis Investigative Site Frankfurt 60488 Germany Details
Novartis Investigative Site Gerlingen 70839 Germany Details
Novartis Investigative Site Grosshansdorf 22947 Germany Details
Novartis Investigative Site Koeln 51109 Germany Details
Novartis Investigative Site Ulm 89081 Germany Details
Novartis Investigative Site Heraklion Crete 711 10 Greece Details
Novartis Investigative Site Thessaloniki 57001 Greece Details
Novartis Investigative Site Torokbalint Pest 2045 Hungary Details
Novartis Investigative Site Ramat Gan 52621 Israel Details
Novartis Investigative Site Lucca LU 55100 Italy Details
Novartis Investigative Site Rozzano MI 20089 Italy Details
Novartis Investigative Site Aviano PN 33081 Italy Details
Novartis Investigative Site Nagoya Aichi 464 8681 Japan Details
Novartis Investigative Site Himeji Hyogo 670-8520 Japan Details
Novartis Investigative Site Yokohama-city Kanagawa 241-8515 Japan Details
Novartis Investigative Site Chuo ku Tokyo 104 0045 Japan Details
Novartis Investigative Site Osaka 545-8586 Japan Details
Novartis Investigative Site Amman 11941 Jordan Details
Novartis Investigative Site Seoul Seocho Gu 06591 Korea, Republic of Details
Novartis Investigative Site Seoul 03722 Korea, Republic of Details
Novartis Investigative Site Seoul 05505 Korea, Republic of Details
Novartis Investigative Site Ashrafieh 166830 Lebanon Details
Novartis Investigative Site Amsterdam 1081 HV Netherlands Details
Novartis Investigative Site Groningen 9713 GZ Netherlands Details
Novartis Investigative Site Maastricht 6229 HX Netherlands Details
Novartis Investigative Site Gdansk 80 952 Poland Details
Novartis Investigative Site Rzeszow 35-021 Poland Details
Novartis Investigative Site Warszawa 02 781 Poland Details
Novartis Investigative Site Pushkin Saint Petersburg 196603 Russian Federation Details
Novartis Investigative Site St Petersburg 197758 Russian Federation Details
Novartis Investigative Site Singapore 168583 Singapore Details
Novartis Investigative Site Malaga Andalucia 29010 Spain Details
Novartis Investigative Site Badalona Catalunya 08916 Spain Details
Novartis Investigative Site Valencia Comunidad Valenciana 46014 Spain Details
Novartis Investigative Site La Coruna Galicia 15006 Spain Details
Novartis Investigative Site Madrid 28034 Spain Details
Novartis Investigative Site Madrid 28040 Spain Details
Novartis Investigative Site Madrid 28041 Spain Details
Novartis Investigative Site Madrid 28222 Spain Details
Novartis Investigative Site Tainan 70403 Taiwan Details
Novartis Investigative Site Taipei 103616 Taiwan Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field